AARSD1

Across TCGA pan-cancer cohorts, AARSD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AARSD1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AARSD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AARSD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where AARSD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.776	1.000	.001	19	view →
LSCC	OS	Median	III,IV	0.694	1.000	.001	12	view →
GBM	OS	Median	All	0.221	0.516	.013	8	view →
PDAC	DFS	Quartile	All	0.919	0.568	.007	4	view →
LUAD	OS	Tertile	All	1.000	0.900	.034	4	view →
HNSC	DFS	Tertile	IV	0.854	0.532	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AARSD1–CCRCC (OS)

Open the CCRCC breakdown →